亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A living WHO guideline on drugs for covid-19

指南 利托那韦 医学 2019年冠状病毒病(COVID-19) 背景(考古学) 随机对照试验 临床试验 梅德林 重症监护医学 家庭医学 内科学 病毒载量 人类免疫缺陷病毒(HIV) 病理 疾病 传染病(医学专业) 法学 政治学 古生物学 抗逆转录病毒疗法 生物
作者
Arnav Agarwal,Beverley J. Hunt,Miriam Stegemann,Bram Rochwerg,François Lamontagne,Reed Siemieniuk,Thomas Agoritsas,Lisa Askie,Lyubov Lytvyn,Yee‐Sin Leo,Helen Macdonald,Linan Zeng,Ahmed Alhadyan,A. Muna,Wagdy Amin,André Ricardo Araújo da Silva,Diptesh Aryal,Fabián Alberto Jaimes Barragán,Frédérique Jacquerioz Bausch,Erlina Burhan,Carolyn S. Calfee,Maurizio Cecconi,Binila Chacko,Duncan Chanda,Vu Quoc Dat,An De Sutter,Bin Du,Stephen B. Freedman,Heike Geduld,Patrick O. Gee,Muhammad Mohsin Haider,Matthias Götte,Nerina Harley,Madiha Hashmi,David S.C. Hui,Mohamed Ismail,Fyezah Jehan,Sushil K. Kabra,Seema Kanda,Yae‐Jean Kim,Niranjan Kissoo,Sanjeev Krishna,Krutika Kuppalli,Arthur Kwizera,Marta Lado Castro-Rial,Thiago Lisboa,Rakesh Lodha,Imelda Mahaka,Hela Manai,Marc Mendelson,Giovanni Battista Migliori,G Miño,Emmanuel Nsutebu,Jessica Peter,Jacobus Preller,N. Pshenichnaya,Nida Qadir,Shalini Sri Ranganathan,Pryanka Relan,Jamie Rylance,Saniya Sabzwari,Rohit Sarin,Manu Shankar‐Hari,Mike Sharland,Yinzhong Shen,João Paulo Souza,Ronald Swanstrom,Tshokey Tshokey,Sebastián Ugarte,Timothy M. Uyeki,Evangelina Vázquez Curiel,Sridhar Venkatapuram,Dubula Vuyiseka,Ananda Wijewickrama,Lien Tran,Dena Zeraatkar,Jessica Bartoszko,Long Ge,Romina Brignardello‐Petersen,Andrew Owen,Pierre Guy,Janet Dı́az,Letícia Kawano-Dourado,Michael Jacobs,Per Olav Vandvik
标识
DOI:10.1136/bmj.m3379
摘要

Abstract Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing earlier versions (available as data supplements). New recommendations will be published as updates to this guideline. Clinical question What is the role of drugs in the treatment of patients with covid-19? Context The evidence base for therapeutics for covid-19 is evolving with numerous randomised controlled trials (RCTs) recently completed and underway. Emerging SARS-CoV-2 variants and subvariants are changing the role of therapeutics. What is new? The guideline development group (GDG) defined 1.5% as a new threshold for an important reduction in risk of hospitalisation in patients with non-severe covid-19. Combined with updated baseline risk estimates, this resulted in stratification into patients at low, moderate, and high risk for hospitalisation. New recommendations were added for moderate risk of hospitalisation for nirmatrelvir/ritonavir, and for moderate and low risk of hospitalisation for molnupiravir and remdesivir. New pharmacokinetic evidence was included for nirmatrelvir/ritonavir and molnupiravir, supporting existing recommendations for patients at high risk of hospitalisation. The recommendation for ivermectin in patients with non-severe illness was updated in light of additional trial evidence which reduced the high degree of uncertainty informing previous guidance. A new recommendation was made against the antiviral agent VV116 for patients with non-severe and with severe or critical illness outside of randomised clinical trials based on one RCT comparing the drug with nirmatrelvir/ritonavir. The structure of the guideline publication has also been changed; recommendations are now ordered by severity of covid-19. About this guideline This living guideline from the World Health Organization (WHO) incorporates new evidence to dynamically update recommendations for covid-19 therapeutics. The GDG typically evaluates a therapy when the WHO judges sufficient evidence is available to make a recommendation. While the GDG takes an individual patient perspective in making recommendations, it also considers resource implications, acceptability, feasibility, equity, and human rights. This guideline was developed according to standards and methods for trustworthy guidelines, making use of an innovative process to achieve efficiency in dynamic updating of recommendations. The methods are aligned with the WHO Handbook for Guideline Development and according to a pre-approved protocol (planning proposal) by the Guideline Review Committee (GRC). A box at the end of the article outlines key methodological aspects of the guideline process. MAGIC Evidence Ecosystem Foundation provides methodological support, including the coordination of living systematic reviews with network meta-analyses to inform the recommendations. The full version of the guideline is available online in MAGICapp and in PDF on the WHO website, with a summary version here in The BMJ . These formats should facilitate adaptation, which is strongly encouraged by WHO to contextualise recommendations in a healthcare system to maximise impact. Future recommendations Recommendations on anticoagulation are planned for the next update to this guideline. Updated data regarding systemic corticosteroids, azithromycin, favipiravir and umefenovir for non-severe illness, and convalescent plasma and statin therapy for severe or critical illness, are planned for review in upcoming guideline iterations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
blueskyzhi完成签到,获得积分10
刚刚
10秒前
15秒前
生动丑应助科研通管家采纳,获得10
16秒前
完美世界应助科研通管家采纳,获得10
16秒前
我是老大应助科研通管家采纳,获得10
16秒前
英俊的铭应助科研通管家采纳,获得10
16秒前
科研通AI5应助科研通管家采纳,获得10
16秒前
16秒前
16秒前
完美世界应助科研通管家采纳,获得10
16秒前
科研通AI2S应助科研通管家采纳,获得10
16秒前
19秒前
27秒前
ZaZa完成签到,获得积分10
29秒前
wyuanhu完成签到,获得积分10
34秒前
小芭乐完成签到 ,获得积分10
34秒前
奋斗的舒芙蕾完成签到,获得积分10
39秒前
43秒前
开心的瘦子完成签到,获得积分20
49秒前
JOSIELO完成签到 ,获得积分10
49秒前
50秒前
54秒前
程小柒完成签到 ,获得积分10
59秒前
1分钟前
1分钟前
Ghiocel完成签到,获得积分10
1分钟前
1分钟前
佟语雪完成签到,获得积分10
1分钟前
轻松的惜芹应助喂喂采纳,获得10
1分钟前
淳于如雪发布了新的文献求助10
1分钟前
LLL完成签到 ,获得积分10
1分钟前
yar应助淳于如雪采纳,获得10
1分钟前
Koking关注了科研通微信公众号
1分钟前
1分钟前
淳于如雪完成签到,获得积分20
1分钟前
lv发布了新的文献求助10
1分钟前
我是老大应助吴嘉俊采纳,获得10
1分钟前
1分钟前
在水一方应助阿九采纳,获得10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990012
求助须知:如何正确求助?哪些是违规求助? 3532049
关于积分的说明 11256153
捐赠科研通 3270925
什么是DOI,文献DOI怎么找? 1805123
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216